Literature DB >> 9931343

A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2).

J M Serratosa1, P Gómez-Garre, M E Gallardo, B Anta, D B de Bernabé, D Lindhout, P B Augustijn, C A Tassinari, R M Malafosse, M Topcu, D Grid, C Dravet, S F Berkovic, S R de Córdoba.   

Abstract

Progressive myoclonus epilepsy of the Lafora type or Lafora disease (EPM2; McKusick no. 254780) is an autosomal recessive disorder characterized by epilepsy, myoclonus, progressive neurological deterioration and glycogen-like intracellular inclusion bodies (Lafora bodies). A gene for EPM2 previously has been mapped to chromosome 6q23-q25 using linkage analysis and homozygosity mapping. Here we report the positional cloning of the 6q EPM2 gene. A microdeletion within the EPM2 critical region, present inhomozygosis in an affected individual, was found to disrupt a novel gene encoding a putative protein tyrosine phosphatase (PTPase). The gene, denoted EPM2, presents alternative splicing in the 5' and 3' end regions. Mutational analysis revealed that EPM2 patients are homozygous for loss-of-function mutations in EPM2. These findings suggest that Lafora disease results from the mutational inactivation of a PTPase activity that may be important in the control of glycogen metabolism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9931343     DOI: 10.1093/hmg/8.2.345

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  77 in total

Review 1.  Glycogen phosphorylation and Lafora disease.

Authors:  Peter J Roach
Journal:  Mol Aspects Med       Date:  2015-08-13

2.  Glycogen metabolism in tissues from a mouse model of Lafora disease.

Authors:  Wei Wang; Hannes Lohi; Alexander V Skurat; Anna A DePaoli-Roach; Berge A Minassian; Peter J Roach
Journal:  Arch Biochem Biophys       Date:  2006-11-03       Impact factor: 4.013

3.  Mutations in the NHLRC1 gene are the common cause for Lafora disease in the Japanese population.

Authors:  Shweta Singh; Toshimitsu Suzuki; Akira Uchiyama; Satoko Kumada; Nobuko Moriyama; Shinichi Hirose; Yukitoshi Takahashi; Hideo Sugie; Koichi Mizoguchi; Yushi Inoue; Kazue Kimura; Yukio Sawaishi; Kazuhiro Yamakawa; Subramaniam Ganesh
Journal:  J Hum Genet       Date:  2005-07-15       Impact factor: 3.172

4.  Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin.

Authors:  Matthew S Gentry; Carolyn A Worby; Jack E Dixon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-01       Impact factor: 11.205

Review 5.  E3 ubiquitin ligases in protein quality control mechanism.

Authors:  Deepak Chhangani; Ajay Prakash Joshi; Amit Mishra
Journal:  Mol Neurobiol       Date:  2012-05-19       Impact factor: 5.590

6.  A bioassay for Lafora disease and laforin glucan phosphatase activity.

Authors:  Amanda R Sherwood; Mary Beth Johnson; Antonio V Delgado-Escueta; Matthew S Gentry
Journal:  Clin Biochem       Date:  2013-09-06       Impact factor: 3.281

7.  Astrocytes: new players in progressive myoclonus epilepsy of Lafora type.

Authors:  Carla Rubio-Villena; Rosa Viana; Jose Bonet; Maria Adelaida Garcia-Gimeno; Marta Casado; Miguel Heredia; Pascual Sanz
Journal:  Hum Mol Genet       Date:  2018-04-01       Impact factor: 6.150

8.  Phosphate incorporation during glycogen synthesis and Lafora disease.

Authors:  Vincent S Tagliabracci; Christian Heiss; Chandra Karthik; Christopher J Contreras; John Glushka; Mayumi Ishihara; Parastoo Azadi; Thomas D Hurley; Anna A DePaoli-Roach; Peter J Roach
Journal:  Cell Metab       Date:  2011-03-02       Impact factor: 27.287

9.  STARCH-EXCESS4 is a laforin-like Phosphoglucan phosphatase required for starch degradation in Arabidopsis thaliana.

Authors:  Oliver Kötting; Diana Santelia; Christoph Edner; Simona Eicke; Tina Marthaler; Matthew S Gentry; Sylviane Comparot-Moss; Jychian Chen; Alison M Smith; Martin Steup; Gerhard Ritte; Samuel C Zeeman
Journal:  Plant Cell       Date:  2009-01-13       Impact factor: 11.277

Review 10.  Lafora disease - from pathogenesis to treatment strategies.

Authors:  Felix Nitschke; Saija J Ahonen; Silvia Nitschke; Sharmistha Mitra; Berge A Minassian
Journal:  Nat Rev Neurol       Date:  2018-10       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.